← All trials
NCT04397679
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Mar 11, 2022
- Completion date
- Sep 11, 2022
- First posted
- May 22, 2020
- Last posted
- May 22, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wayne State UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Wayne State UniversityOverall official - principal investigator
- Wayne State UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.